This reporter cell (Cat. No.CHEK-ATF128) was incubated with serial dilutions of human GLP-2R agonist. The EC50 of human GLP-2R agonist (Glepaglutide) was approximately 0.1281 nM. ●GLP-2R激动剂筛选应用案例-FOLD Bioactivity ...
●GLP-2R激动剂筛选应用案例-RLU Bioactivity analysis of human GLP-2R agonist (RLU). This reporter cell (Cat. No.CHEK-ATF128) was incubated with serial dilutions of human GLP-2R agonist. The EC50 of human GLP-2R agonist (Glepaglutide) was approximately 0.1281 nM. ●GLP-2R激动剂筛选应...
peptide GLP-2 agonistThe new GLP 2 analog where medicine movement property is improved and it states the use in diseased remedying concerning.< Choice figure >It is notアラガーサミー,スダーコディジャン,グワンチェンリビエール,ピエール...
The invention relates to compounds having agonist activity at the GLP-1 (glucagon- like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis...
[6]. Chen Y, Chen J, Zhang S, et al. Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on 'time in range' in patients with type 2 diabetes[J]. Front Pharmacol, 2024, 15:1370594. [7]. Takeishi S, Tsuboi H, Takekoshi S. Comparison of tofogliflozin 20 mg...
GLP-1(胰高血糖素样肽-1,glucagon-like peptide-1)于1987年被发现,是血糖稳态调节的重要靶点;而GLP-1RA(胰高血糖素样肽-1受体激动剂,glucagon-like peptide-1 receptor agonist, GLP-1RA)则被研发用于改善2型糖尿病的一些关键性病理生理缺陷,并具有减少心血管死亡、改善动脉粥样硬化、减轻体质量、降低收缩压等...
GLP-2 (3-33) is a fragment polypeptide sequence generated by dipeptidyl peptidase IV (DPPIV), which is a Partial agonist (EC50=5.8 nM) with potential competitive antagonistic properties against GLP-2 receptor. The polypeptide sequence contains 31 amino acids. Purity (HPLC) ≥98.0% Single impuri...
[8] Merck steps into NASH space with early data for its GLP-1/glucagon receptor co-agonist. Retrieved June 14, 2023, from https://endpts.com/merck-steps-into-liver-disease-space-with-early-data-for-its-glp-1-glucagon-receptor-co-agonist/ ...
Therefore, the invention relates to the use of a GLP-2 receptor agonist for the general maturation of the intestines of the premature newborn to accelerate and improve oral feeding as well as for the treatment of damaged tissue that may arise in these infants. In a further aspect, the ...
The present invention relates to compositions and peptides having agonist activity towards both the human GLP-1 receptor and the human GLP-2 receptor, wherein the relative agonist activity of the dual peptide towards the human GLP-1 receptor (GLP-1R relative ) is at least 0.01, and wherein ...